NCT07390643

The DISCOVER Study

Determining ImpactS of Multi-Cancer Early detectiOn Tests oVER Time in Symptomatic Patients: The DISCOVER Study

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 22 Years
• Healthy volunteers: Accepted

Summary

The purpose of this research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer. The name of the screening blood test being studied is: -GRAIL Galleri MCED test

Detailed description

The purpose of this pilot research study is to evaluate the possible benefits of screening with an investigational, but commercially available blood test designed to detect many types of cancer. "Investigational" means that this test is being studied and is not approved or cleared by the Food and Drug Administration (FDA). The multi-cancer early detection test looks for small pieces of genetic material, called DNA (deoxyribonucleic acid), in the blood that may indicate the presence of cancer, and the test may also be able to suggest what type of cancer is present. The research study procedures include screening for eligibility, in-clinic visit, blood tests, and questionnaires. It is expected that about 110 people will take part in this research study.

Conditions

• Cancer
• Cancer Diagnosis

Interventions

Type	Name	Description
DEVICE	GRAIL Galleri MCED test	A multi-cancer early detection (MCED) blood test.

Timeline

• Start date: 2026-07-01
• Primary completion: 2027-01-31
• Completion: 2028-01-31
• First posted: 2026-02-05
• Last updated: 2026-02-05

Locations

1 site across 1 country: United States